ArticleBritish journal of cancer2026
Population-based nasopharyngeal carcinoma survival in southern China.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-time AI-assisted quality control during nasopharyngolaryngoscopy: a randomized controlled trial.NPJ digital medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundFew population-based studies on nasopharyngeal carcinoma (NPC) prognosis exist. Such real-world data with complete follow-up are needed to enable accurate estimation of survival probabilities and monitor progress in early detection and treatment.
methodsIn a population-based study of 2529 patients with incident NPC in southern China diagnosed in 2010-2013, we developed a passive-active-passive follow-up strategy involving data linkage and direct contact to track patients' vital status, cause of death, and migration through December 31, 2018. We calculated 5-year survival probabilities by the Kaplan-Meier method, and estimated avoidable deaths comparing hypothetical scenarios and real-world observations.
resultsEarly-stage (I-II) patients accounted for 11·5%, and 21·1% were treated in medical-university-affiliated or province-level hospitals. With a mean follow-up time of 5·5 years after diagnosis (98.3% complete), 5-year overall and NPC-specific survival probabilities were 70·1% and 74·5%. The 5-year overall survival probabilities for stage I, II, III, IVa, IVb, and IVc were 91·3%, 87·8%, 79·8%, 63·9%, 57·7%, and 34·4%, respectively. Survival of non-metastatic (I-IVb) population-based patients diagnosed in 2010-2013 was comparable to that of a hospital-based southern Chinese NPC cohort diagnosed in 1997-2007. Based on observed data, if all patients were diagnosed at stages I-II, then total avoidable deaths within 5 years after diagnosis would be 156 per 1000 patients.
conclusionsReal-world population-based NPC survival lags behind that of large hospital-based cohorts, but earlier diagnosis has the potential to substantially reduce mortality from NPC. Our results highlight the importance of improving the accessibility of health resources and promoting early detection of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.